I-MAB (IMAB) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Debt-to-Equity?

I-MAB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.26 Mil. I-MAB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11.49 Mil. I-MAB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $240.63 Mil. I-MAB's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for I-MAB's Debt-to-Equity or its related term are showing as below:

IMAB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.71 Med: 0 Max: 0.08
Current: 0.08

During the past 7 years, the highest Debt-to-Equity Ratio of I-MAB was 0.08. The lowest was -0.71. And the median was 0.00.

IMAB's Debt-to-Equity is ranked better than
64.13% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs IMAB: 0.08

I-MAB Debt-to-Equity Historical Data

The historical data trend for I-MAB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Debt-to-Equity Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.07

0.03

0.08

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial								0.03	0.03	0.03	0.03	0.08

Competitive Comparison of I-MAB's Debt-to-Equity

For the Biotechnology subindustry, I-MAB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where I-MAB's Debt-to-Equity falls into.

I-MAB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

I-MAB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.263	+	11.486)	/	240.631
	=	0.08

I-MAB's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.263	+	11.486)	/	240.631
	=	0.08

I-MAB (NAS:IMAB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

I-MAB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of I-MAB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.